로딩 중…
StockDiggingStockDigging

Becton, Dickinson and Company

BDX· NYSE
$180.84-0.30%
2026-09-18

Financials

Valuation Metrics

Becton, Dickinson and Company's Market Cap is $49.83B. At end of 2025 it was $43.49B. Ranked #319 of 3,119 in US market (top 10%), #232 of 1,656 on NYSE (top 14%), #18 of 205 in Health Care Equipment & Services (top 9%) by Market Cap.

Investment Metrics(as of 2026-09-19)

MetricValue
Size
Market Cap$49.83B
Revenue$20.84B
Net Income$941M
Total Assets$50.73B
Net Assets$24.42B
Employees70,000
Value
P/E52.95x
P/B2.04x
P/S2.39x
EV/EBITDA16.92x
FCF Yield5.23%
Profitability
ROE3.85%
ROA1.85%
Op. Margin9.83%
Revenue Growth-2.56%
Earnings Growth-40.63%
Financial Health
Debt Ratio107.77%
Total Debt$16.81B
FCF$2.61B
Cash$708M
Current Ratio0.87x
Net Debt/EBITDA4.13x
Dividend
Div. Yield3.53%
Div. Growth9.92%
Performance
1Y Return22.78%
1M Return-3.60%
From 52W High-6.33%
1Y MDD-24.10%
Trading
Volume2,360,518 shares
Trading Value$427M
Per Share
EPS$3.42
BPS$88.61

Company Info

CEO Mr. Thomas E. Polen Jr.
Employees 70,000
HQ Franklin Lakes, United States

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.